Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Merit Medical Systems ( (MMSI) ).
Merit Medical Systems announced preliminary unaudited revenue for 2024 ranging from $1.355 billion to $1.357 billion, reflecting an increase of 7.7% to 7.9% compared to 2023. The company also reported a preliminary constant currency revenue increase of 8.4% to 8.6% year-over-year and plans to release full financial results for 2024 and guidance for 2025 on February 25, 2025. This growth underscores Merit’s strong performance in the healthcare technology sector, potentially impacting its market position and offering positive implications for stakeholders.
More about Merit Medical Systems
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,400 people worldwide.
YTD Price Performance: -0.45%
Average Trading Volume: 428,594
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.6B
See more data about MMSI stock on TipRanks’ Stock Analysis page.
